ReviewNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2013
An evaluation of the evidence that methamphetamine abuse causes cognitive decline in humans.
Review in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 119 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
119 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Translational medications development for methamphetamine use disorder: A systematic review of preclinical, human laboratory, and clinical research.Pharmacological reviews · 2026Pooled it
- Molecular mechanisms of programmed cell death in methamphetamine-induced neuronal damage.Frontiers in pharmacology · 2022Pooled it
- Khat and neurobehavioral functions: A systematic review.PloS one · 2021Pooled it
- Ecological momentary assessments for self-monitoring and counseling to optimize methamphetamine treatment and sexual risk reduction outcomes among gay and bisexual men.Journal of substance abuse treatment · 2018Trial
- Ibudilast attenuates subjective effects of methamphetamine in a placebo-controlled inpatient study.Drug and alcohol dependence · 2016Trial
- Concurrent chronic methamphetamine exposure may influence behavioral outcomes following repetitive mild traumatic brain injury.Psychopharmacology · 2026Article
- Methamphetamine hijacks chaperone-mediated autophagy to degrade GPX4, driving ferroptosis-precipitated cognitive decline and addictive pathogenesis.Acta neuropathologica communications · 2026Article
- The effect of 6 Hz transcranial alternating current stimulation over the prefrontal cortex on reward learning in men with methamphetamine use disorder: A pilot randomised double-blind trial.General psychiatry · 2026Article
- Fronto-striatal neurometabolite signatures of impulsivity in early abstinence from methamphetamine.NeuroImage. Clinical · 2026Article
- 96-h methamphetamine self-administration elicits striatal dopamine depletion in male and female rats: a model of binge-like use.Psychopharmacology · 2026Article
- The mesocorticolimbic system in stimulant use disorder.Molecular psychiatry · 2025Review
- Temporal changes in cognitive functions and associated factors among stimulant users: a 12-month, prospective study.Scientific reports · 2025Article
- When the Mind Cannot Shift: Cognitive Flexibility Impairments in Methamphetamine-Dependent Individuals.Behavioral sciences (Basel, Switzerland) · 2025Article
- Differential Impact of Methamphetamine Dependence and Social Media Overuse on Cognitive Control: Based on the Dual Mechanisms of Control Theory.Behavioral sciences (Basel, Switzerland) · 2025Article
- Peripheral Blood Exosomal miR-184-3p in Methamphetamine Use Disorder: Biomarker Potential and CRTC1-Mediated Neuroadaptation.Current issues in molecular biology · 2025Article
- Methamphetamine produces behavioral flexibility deficits that are attenuated by COX-2 inhibition in both male and female rats.Addiction neuroscience · 2025Article
- Association of Cognitive Impairment and Peripheral Inflammation in Methamphetamine-dependent Patients: A Cross-sectional Study on Neuroinflammatory Markers TNF-α and IL-6.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2025Article
- Genes, Cognition, and Their Interplay in Methamphetamine Use Disorder.Biomolecules · 2025Review
- Decreasing β-Catenin Leads to Altered Endothelial Morphology, Increased Barrier Permeability and Cognitive Impairment During Chronic Methamphetamine Exposure.International journal of molecular sciences · 2025Article
- An exploration of desired abstinent and non-abstinent recovery outcomes among people who use methamphetamine.Harm reduction journal · 2025Article
59 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Methamphetamine (MA) is one of the most commonly abused illicit substances worldwide. Among other problems, abuse of the drug has been associated with reduced cognitive function across several domains. However, much of the literature has not attempted to differentiate cognitive difficulties caused by MA abuse from preexisting cognitive difficulties that are likely caused by other factors. Here, we address this question, evaluating evidence for a priori hypotheses pertaining to six lines of research: (a) animal studies; (b) cross-sectional human studies; (c) a twin study; (d) studies of changes in cognition with abstinence from MA; (e) studies of changes in brain structure and function with abstinence from MA; and (f) studies of the relationship between the severity of MA abuse and the extent of cognitive deficits observed. Overall the findings were mixed, with some support for a causal relationship between MA abuse and cognitive decline, and other findings suggesting that there is no relationship. The preponderance of the data, however, does support the possibility that MA abuse causes cognitive decline, of unknown duration, in at least some users of the drug. When averaged across individuals, this decline is likely to be mild in early-to-middle adulthood. However, moderator variables are likely to contribute to the presence and/or severity of cognitive decline exhibited by a given individual.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.